Perioperative Parenteral Tranexamic Acid in Liver Tumor Resection: A Prospective Randomized Trial Toward a “Blood Transfusion”-Free Hepatectomy


    loading  Checking for direct PDF access through Ovid

Abstract

Objective:To examine the feasibility of a real “blood transfusion”-free hepatectomy in a large group of patients with liver tumors.Summary Background Data:Bleeding control and blood transfusion remains problematic in liver resection. A real “blood transfusion”-free hepatectomy in a large group of patients has rarely been reported. The impact of tranexamic acid (TA), an antifibrinolytic agent, on blood transfusion in liver resection is unknown.Methods:A prospective double-blind randomized trial was performed on elective liver tumor resections. In group A, TA 500 mg was intravenously administered just before operation followed by 250 mg, every 6 hours, for 3 days. In group B, only placebo was given. The patients' background, blood transfusion rates, and early postoperative results in the 2 groups were compared. Factors that influenced blood requirement were analyzed.Results:There were 108 hepatectomies in group A and 106 hepatectomies in group B. The patients' backgrounds, operative procedures, and hepatectomy extent did not significantly differ between the 2 groups. Although the differences of the operative morbidity and postoperative stay were not significant, a significantly lower amount of operative blood loss, lower blood transfusion rate, shorter operative time, and lower hospital costs were found in group A patients. No patient in group A received blood transfusion. No hospital mortality occurred in either group. Tumor size and use of TA were independent factors that influenced blood transfusion.Conclusions:Perioperative parenteral use of TA reduced the amount of operative blood loss and the need for blood transfusion in elective liver tumor resection. A real “blood transfusion”-free hepatectomy may be feasible with the assistance of parenteral TA.

    loading  Loading Related Articles